CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Mylan Pharmaceuticals, Inc. vs. Merck Sharp & Dohme Corp. et al.

๐Ÿ“ก 5G SEP โ€ข ETSI Declared

Explore the PTAB proceeding IPR2020-00040 filed by Mylan Pharmaceuticals, Inc. on 2019-10-30. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2020-00040

Filing Date

2019-10-30

Accorded Filing Date

2019-11-14

Institution Decision Date

2020-05-12

Last Modified Date

โ€”

Proceeding Type

IPR

Termination Date

2021-05-07

Trial Status

Final Written Decision

Parties & Counsel

Patent Owner / Respondent

Patent Information

1 Patent Involved
Respondent Application Number 10874992
Respondent Patent Number 7326708
Legal Expiration Date
2026-11-24 Expiring Soon (4 days)
Patent Term Adjustment (PTA) +884 Days Awarded
Injunction Viability (35 U.S.C. ยง 283) Statutorily Barred
Respondent Inventor Stephen Howard Cypes et al
Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Tribunal & APJ Panel Intelligence

Board Intelligence

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Decisions Rendered

2 Total

Proceeding Status

Final Written Decision

Administrative Patent Judges (APJ Panel)

Panel assignment tracked upon institution decision entry

Board Decisions & Rulings (2)

Affirmed 2023-09-06
Other: Fed Circuit mandate
35 U.S.C. Trial Decision
Termination 2021-05-07
Termination Decision Document
35 USC 312, 35 USC 318, 37 CFR 42.100

Address and Attorney/Agent Information

39 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name MERCK
Customer Number โ€”
Address P O BOX 2000, RAHWAY, NJ, 07065-0907, UNITED STATES

Attorney / Agent Information

Reg # Name Phone
34398 Mary Morry +1 732-594-1935
36036 John Todaro +1 732-594-0125
36436 Sylvia Ayler +1 732-594-4909
36502 Catherine Fitch +1 732-594-4283
42068 Dianne Pecoraro +1 732-594-1249
42452 Anna Cocuzzo +1 --
42876 Eric Meade +1 732-594-1045
43039 John Reilly +1 732-594-6914

Global Patent Family Cross-Litigation Radar

CasLoc 360ยฐ Radar 2 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

๐Ÿ‡บ๐Ÿ‡ธ
U.S. District Courts 6 proceedings
๐Ÿ›๏ธ
USPTO PTAB Trials 3 proceedings
๐Ÿ‡ช๐Ÿ‡บ
Unified Patent Court (UPC) Counterparts in force
๐Ÿ‡ฉ๐Ÿ‡ช
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (2): ๐Ÿ‡บ๐Ÿ‡ธ US
Parallel Proceedings Across Jurisdictions (9 found):
PTAB: 3 U.S. Courts: 6
USPTO PTAB Trial 2020-06-12
IPR2020-01072

Sun Pharmaceutical Industries Ltd. et al. v. Merck Sharp & Dohme Corp. et al.

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2020-06-11
IPR2020-01060

Dr. Reddy's Laboratories, Inc. et al. v. Merck Sharp & Dohme Corp. et al.

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2020-06-10
IPR2020-01045

Teva Pharmaceuticals USA, Inc. v. Merck Sharp & Dohme Corp.

Asserted Patent
Status: Terminated-Settled
U.S. District Court 2019-08-09
1:19-cv-01489

Merck Sharp & Dohme Corp. v. Mylan Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2019-02-13
1:19-cv-00318

Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA, Inc.

Asserted Patent
Status: DED
U.S. District Court 2019-02-13
1:19-cv-00319

Merck Sharp & Dohme Corp. v. Sun Pharmaceutical Industries Ltd.

Asserted Patent
Status: DED
U.S. District Court 2019-02-13
1:19-cv-00310

Merck Sharp & Dohme Corp. v. Alvogen Pine Brook LLC

Asserted Patent
Status: DED
U.S. District Court 2019-02-13
1:19-cv-00317

Merck Sharp & Dohme Corp. v. Watson Laboratories, Inc.

Asserted Patent
Status: DED
U.S. District Court 2019-02-13
1:19-cv-00312

Merck Sharp & Dohme Corp. v. Sandoz Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Standard Essential Patent (SEP) & FRAND Intelligence

5G SEP โ€ข ETSI Declared High-Probability SEP Action

Essential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation

FRAND Encumbered
Essential Standard 4G / 5G LTE Generation: 5G
Standard Setting Org (SSO) ETSI / 3GPP Essential specification under ETSI / 3GPP governance
FRAND Commitment Committed Fair, Reasonable & Non-Discrim.
Known Patent Pools Avanci / Sisvel / Via Licensing Coverage Applicable Declarant: Sharp

Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)

Permanent Injunction Restricted

Asserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.

โœ“ Patentee bound by SSO IPR Policy (ETSI Annex 6 / IEEE Patent Policy).
โœ“ Right to demand global FRAND portfolio determination.
โœ“ Non-discrimination defense: check licensing terms offered to competing implementers.

Proceeding Documents

200
97

Other: Fed Circuit mandate OTHER

2023-09-06 FILING PARTY: BOARD
96

Other: other court decision OTHER

2023-09-06 FILING PARTY: BOARD
95

Other: other court decision OTHER

2023-09-06 FILING PARTY: BOARD
94

Notice of Appeal of Petitioner Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd Paper

2021-07-08 FILING PARTY: PETITIONER
92

Petitioner's Notice of Appeal Paper

2021-07-08 FILING PARTY: PETITIONER

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc